Evidence map›Paper›PMID 28351930›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.

Shumei Kato, Aaron Goodman, Vighnesh Walavalkar, Donald A Barkauskas, Andrew Sharabi, Razelle Kurzrock

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 549 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
549citing papers in PubMed, 5 pooled it
48.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

549 citing papers in PubMed, 5 syntheses or guidelines pooled it, 843 citations in OpenAlex.

  1. Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Current and future immunotherapies for NSCLC.Journal of hematology & oncology · 2026
    Review
  20. Article

489 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Shumei KatoCenter for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California, San Diego Moores Cancer Center, La Jolla, California. smkato@ucsd.edu.
Aaron GoodmanCenter for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California, San Diego Moores Cancer Center, La Jolla, California.
Vighnesh WalavalkarDepartment of Pathology, University of California San Diego Moores Cancer Center, La Jolla, California.
Donald A BarkauskasBiostatistics Division, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Andrew SharabiCenter for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California, San Diego Moores Cancer Center, La Jolla, California.
Razelle KurzrockCenter for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California, San Diego Moores Cancer Center, La Jolla, California.
Center for Personalized Cancer Treatment · NLUniversity of California San Diego · USUniversity of Southern California · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
NCI NIH HHS P30 CA016672NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenBiomarkers, TumorCell Cycle ProteinsCTLA-4 AntigenErbB ReceptorsFemaleGene Expression Regulation, NeoplasticGenomicsHumansImmunotherapyMaleMiddle AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedatezolizumabB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCell Cycle ProteinsCTLA-4 AntigenEGFR protein, humanErbB ReceptorsMDM2 protein, humanMDM4 protein, humanNuclear ProteinsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2

Identifiers

PMID28351930
PMCPMC5647162
OpenAlexW2601621622

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.